TG Therapeutics | TGTX - Cash And Equivalent


TG Therapeutics reported $442.21M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Biogen USD 3.38B 374.2M Mar/2026
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Curis USD 10.14M 10.14M Jun/2025
Gilead Sciences USD 7.56B 234M Dec/2025
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Novavax USD 228.36M 12.27M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 442.21M 242.7M Mar/2026
Verastem USD 204.99M 67.28M Dec/2025
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026